Does Coconut Oil Blood Pressure Randomized Trial work?

Updated June 2026

Quick Answer

Coconut Oil Blood Pressure Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: This distinction helps explain why higher POA in cholesterol esters, phospholipids, or adipose tissue is often associated with hypertriglyceridemia, abdominal adiposity, insulin resistance, non-alcoholic fatty liver disease, and vascular risk, whereas some studies of free POA or specific phospholipid pools report associations with better insulin sensitivity or lower diabetes risk (–).

Key Takeaways

  • 01This distinction helps explain why higher POA in cholesterol esters, phospholipids, or adipose tissue is often associated with hypertriglyceridemia, abdominal adiposity, insulin resistance, non-alcoholic fatty liver disease, and vascular risk, whereas some studies of free POA or specific phospholipid pools report associations with better insulin sensitivity or lower diabetes risk (–). [Destaillats Frédéric (2026)]
  • 02The sections below organize the evidence by metabolic domain and emphasize the need to distinguish endogenous POA as a marker of lipogenesis from exogenous POA delivered in foods or supplements. [Destaillats Frédéric (2026)]
  • 03lowest quartile of plasma POA had ~2-fold higher triglyceridemia, and POA remained independently associated with both hypertriglyceridemia and abdominal adiposity in multivariable models (). [Destaillats Frédéric (2026)]
  • 04cis 1 2 3 10 Palmitoleic acid (POA; 16:1 n-7 or-9 16:1) is a monounsaturated fatty acid produced primarily through stearoyl-CoA desaturase-1 (SCD1)-mediated desaturation of palmitic acid. [Destaillats Frédéric (2026)]
The current Migaku evidence database contains 2 reusable source documents for Coconut Oil Blood Pressure Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - This distinction helps explain why higher POA in cholesterol esters, phospholipids, or adipose tissue is often associated with hypertriglyceridemia, abdominal adiposity, insulin resistance, non-alcoholic fatty liver disease, and vascular risk, whereas some studies of free POA or specific phospholipid pools report associations with better insulin sensitivity or lower diabetes risk (–). [Destaillats Frédéric (2026); evidence level 3] - The sections below organize the evidence by metabolic domain and emphasize the need to distinguish endogenous POA as a marker of lipogenesis from exogenous POA delivered in foods or supplements. [Destaillats Frédéric (2026); evidence level 3] - lowest quartile of plasma POA had ~2-fold higher triglyceridemia, and POA remained independently associated with both hypertriglyceridemia and abdominal adiposity in multivariable models (). [Destaillats Frédéric (2026); evidence level 3] - cis 1 2 3 10 Palmitoleic acid (POA; 16:1 n-7 or-9 16:1) is a monounsaturated fatty acid produced primarily through stearoyl-CoA desaturase-1 (SCD1)-mediated desaturation of palmitic acid. [Destaillats Frédéric (2026); evidence level 3] - Virgin coconut oil: A comprehensive review of its health impacts and functional food applications [Khan I (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Palmitoleic (16:1 n-7) acid and metabolic health: integrating observational, clinical, and mechanistic evidence
  2. Virgin coconut oil: A comprehensive review of its health impacts and functional food applications